Allakos Inc. (ALLK)
NASDAQ$0.247
Market Cap
$22.07M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
441 of 924
Rank in Industry
260 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
ALLK Insider Trading Activity
ALLK Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $87,935 | 1 | 100 |
Related Transactions
| Radford Harlan Baird | Chief Financial Officer | 0 | $0 | 1 | $87,935 | $-87,935 |
About Allakos Inc.
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab …
Insider Activity of Allakos Inc.
Over the last 12 months, insiders at Allakos Inc. have bought $0 and sold $87,935 worth of Allakos Inc. stock.
On average, over the past 5 years, insiders at Allakos Inc. have bought $0 and sold $142.03M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 222,222 shares for transaction amount of $4M was made by MCKEARN JOHN P () on 2018‑07‑23.
List of Insider Buy and Sell Transactions, Allakos Inc.
| 2024-06-28 | Sale | Radford Harlan Baird | Chief Financial Officer | 87,064 0.0937% | $1.01 | $87,935 | -24.61% | |
| 2021-09-28 | Sale | James Steven P | director | 4,000 0.0075% | $108.12 | $432,480 | -94.75% | |
| 2021-06-14 | Sale | Tomasi Adam | President and COO | 20,000 0.0376% | $91.62 | $1.83M | -15.78% | |
| 2021-06-07 | Sale | Tomasi Adam | President and COO | 2,487 0.0047% | $92.03 | $228,879 | -14.19% | |
| 2021-06-04 | Sale | Alexander Robert | Chief Executive Officer | 23,595 0.044% | $89.64 | $2.11M | -12.39% | |
| 2021-06-04 | Sale | Tomasi Adam | President and COO | 642 0.0012% | $90.26 | $57,947 | -12.39% | |
| 2021-06-04 | Sale | RASMUSSEN HENRIK S MD | Chief Medical Officer | 2,435 0.0045% | $89.60 | $218,176 | -12.39% | |
| 2021-06-03 | Sale | Alexander Robert | Chief Executive Officer | 20,001 0.0378% | $92.13 | $1.84M | -13.45% | |
| 2021-06-02 | Sale | Alexander Robert | Chief Executive Officer | 20,001 0.0369% | $94.55 | $1.89M | -17.34% | |
| 2021-05-19 | Sale | Alexander Robert | Chief Executive Officer | 19,998 0.0374% | $98.93 | $1.98M | -18.90% | |
| 2021-05-18 | Sale | Alexander Robert | Chief Executive Officer | 20,001 0.0377% | $102.31 | $2.05M | -20.84% | |
| 2021-05-17 | Sale | Alexander Robert | Chief Executive Officer | 20,001 0.0369% | $99.68 | $1.99M | -20.43% | |
| 2021-05-10 | Sale | Tomasi Adam | President and COO | 20,000 0.0377% | $96.02 | $1.92M | -14.94% | |
| 2021-04-14 | Sale | Tomasi Adam | President, COO and CFO | 20,000 0.0373% | $107.77 | $2.16M | -23.40% | |
| 2021-04-13 | Sale | Tomasi Adam | President, COO and CFO | 20,000 0.0368% | $103.08 | $2.06M | -21.06% | |
| 2021-04-12 | Sale | Tomasi Adam | President, COO and CFO | 20,000 0.0373% | $104.40 | $2.09M | -20.99% | |
| 2021-04-06 | Sale | RASMUSSEN HENRIK S MD | Chief Medical Officer | 10,000 0.0189% | $111.68 | $1.12M | -24.45% | |
| 2021-04-05 | Sale | RASMUSSEN HENRIK S MD | Chief Medical Officer | 20,000 0.0374% | $113.06 | $2.26M | -26.01% | |
| 2021-04-01 | Sale | RASMUSSEN HENRIK S MD | Chief Medical Officer | 20,000 0.0374% | $114.40 | $2.29M | -26.91% | |
| 2021-03-26 | Sale | JANNEY DANIEL | 17,308 0.0325% | $115.17 | $1.99M | -26.70% |
Total: 80
*Gray background shows transactions not older than one year
Insider Historical Profitability
13.36%
| Alta Partners VIII, L.P. | 10 percent owner | 11519200 12.8931% | $2.85M | 1 | 0 | +13.36% |
| RiverVest Venture Fund III, L.P. | 10 percent owner | 5750506 6.4364% | $1.42M | 1 | 14 | +13.36% |
| JANNEY DANIEL | 56293 0.063% | $13,904.37 | 1 | 6 | +13.36% | |
| MCKEARN JOHN P | director | 1200 0.0013% | $296.40 | 1 | 15 | +13.36% |
Historical Insider Profitability vs. Competitors
$992,222,850 | 90 | -12.52% | $19.2M | |
$6,204,522 | 45 | 1.91% | $19.24M | |
$550,024 | 37 | -2.68% | $20.57M | |
$1,363,112 | 33 | 15.03% | $23.47M | |
$94,084,626 | 29 | -21.08% | $23.99M |
ALLK Institutional Investors: Active Positions
| Increased Positions | 29 | +28.71% | 12M | +16.38% |
| Decreased Positions | 40 | -39.6% | 7M | -10.61% |
| New Positions | 10 | New | 7M | New |
| Sold Out Positions | 13 | Sold Out | 4M | Sold Out |
| Total Postitions | 90 | -10.89% | 74M | +5.76% |
ALLK Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Bvf Inc/Il | $4,635.00 | 18.6% | 16.55M | 0 | 0% | 2024-12-31 |
| Nea Management Company, Llc | $1,721.00 | 6.91% | 6.15M | 0 | 0% | 2024-12-31 |
| Deep Track Capital, Lp | $1,597.00 | 6.41% | 5.7M | +704,282 | +14.09% | 2024-12-31 |
| Fmr Llc | $1,515.00 | 6.08% | 5.41M | +39,904 | +0.74% | 2024-12-31 |
| Lynx1 Capital Management Lp | $1,016.00 | 4.08% | 3.63M | +4M | New | 2024-12-31 |
| Point72 Asset Management, L.P. | $1,006.00 | 4.04% | 3.59M | +2M | +105.4% | 2024-12-31 |
| Vanguard Group Inc | $960.00 | 3.85% | 3.43M | -86,207 | -2.45% | 2024-12-31 |
| Redmile Group, Llc | $844.00 | 3.39% | 3.02M | -62,731 | -2.04% | 2024-12-31 |
| Vivo Capital, Llc | $828.00 | 3.32% | 2.96M | 0 | 0% | 2024-12-31 |
| Logos Global Management Lp | $812.00 | 3.26% | 2.9M | 0 | 0% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.